 |
 About
Us Product
PortfoliosWound
ManagementOther   
|
|
Background APS was established in 2003 by Dr Roy Harris, a protein/biopolymer scientist with over 20 years experience of biopolymer drug delivery and a leading expert in the therapeutic uses of HSA. APS `s platform of products in development are aimed at the major markets of • Wound Management and Tissue Repair • Diabetes • Cancer • Haemostasis • Arthritis APS have purpose built laboratory and office facilities at Biocity Nottingham. Product Portfolios Wound Management Other Capitalizing on the properties intrinsic to HSA that have potential benefit to enhance wound management and repair, APS is developing a range of products using a novel HSA gel formulation (Albigel) for topical administration to external wounds The gels provide an optimum environment for wound healing, maintaining a moist environment and high levels of HSA. They can be produced in a range of sizes, are robust but flexible and are easily moldable to fit over difficult wounds or on the sacrum and heel. Albigel is made entirely from natural products, and is a safe non-toxic, non-allergenic wound dressing. APS`s pilot product is Albigel-P. This has shown outstanding results in preclinical trials and is performing well in phase I/II clinical safety trials in venous leg ulcers. Albigel-P is easy to apply and remove and has been accepted by both clinicians and patients. APS is also developing its lead product, CuGel, a copper based formulation based upon Albigel-P that extends the wound management capabilities of the original gel into other areas of wound repair including anti-infection and the promotion of essential cellular events (eg angiogenesis, re-epithelisation and matrix remodeling) through targeted delivery to the wound site. APS is preparing to take CuGel into Phase II/III human trials in early 2009. It expects to begin commercialising its first products in the treatment of chronic ulcers within 2 years. |
   |
| ©
Advanced Protein Systems 2006 | Site Map
| Privacy | Links
|
|